Autotransfusion Devices Market Size, Share & Industry Analysis, By Product Type (Autotransfusion Systems and Consumables & Accessories), By Application (Cardiovascular Surgeries, Orthopedic Surgeries, Neurological Surgeries, Obstetrics & Gynecological Surgeries, and Others), By End-user (Hospitals and Specialty Clinics & Others), and Regional Forecast, 2024-2032

The global autotransfusion devices market was valued at USD 279.9 million in 2023. The market is projected to grow from USD 293.6 million in 2024 to USD 447.5 million by 2032, exhibiting a CAGR of 5.4% during the forecast period. 

Autotransfusion devices are widely used to collect and reinfuse the patient’s blood. These systems play a major role in cell salvage techniques, enabling autologous blood transfusion to reduce the risk of infections associated with allogeneic blood transfusions. These devices find applications in cardiovascular, orthopedic, neurological, obstetrics & gynecological, and other invasive surgeries. As per the usability of systems, they can be categorized into intraoperative systems, post-operative systems, and dual-mode systems.

The increasing number of surgical procedures across the globe is anticipated to fuel the growth of the market during the forecast period. For instance, according to an article published by the National Institutes of Health (NIH) in 2020, about 310.0 million major surgeries are performed each year across the globe. Furthermore, around 40.0-50.0 million are performed in the U.S. and around 20.0 million in Europe. Moreover, aging population, increasing prevalence of chronic conditions, and the need for advanced blood management systems are expected to boost the global market growth during the forecast period.

The outbreak of the COVID-19 pandemic had a negative impact on the market growth. It showcased a huge decline in revenue due to a decline in the number of surgical procedures. In 2021 and 2022, the market recorded the revival of industry growth. The market is expected to grow exponentially over the forecast period.

Autotransfusion Devices Market Trends

Shift toward Autologous Blood Transfusion is a Prominent Trend

Over the past few years, the market has witnessed a potential shift toward autologous blood transfusion. Allogeneic blood transfusions are highly susceptible to cause adverse effects such as tumor recurrence, post-operative infections, acute lung injury, post-operative cardiac failures, and increased mortality. For instance, according to various patient-based studies, the prevalence of transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI) is estimated to be around 1.0% and 0.1% transfusion cases in the U.S., respectively. Therefore, a shift of preference toward adopting cell salvage can drastically reduce the requirement of allogeneic blood transfusion, thereby lowering the risk of adverse complications.

For instance, according to an article published by the National Institutes of Health in 2022, about 50.0 to 60.0% of all transfusions take place in the surgical setting. Cell salvage is an efficient and cost-effective alternative to intraoperative and postoperative blood transfusions in intensive care medicine. Furthermore, its use in orthopedic patients, trauma patients, and cardiac surgery patients appears to be well-understood and feasible. This is projected to spur the market growth during the forecast period.

Autotransfusion Devices Market Growth Factors

Increasing Number of Surgical Procedures to Boost Market Growth

Intraoperative & post-operative cell salvage and blood transfusions are prime aspects of blood conservation during any surgical procedure. Additionally, the emphasis on avoiding complications associated with allogeneic transfusions and an increasing number of high-bleeding surgeries are projected to drive the growth of the global market during the forecast period.

• For instance, as per an article published by SeamlessMD in 2023, there are more than 138,000 hip and knee surgeries a year in Canada, according to the Canadian Institute for Health Information.

This, combined with the increasing awareness of intraoperative & post-operative blood salvage, is anticipated to offer substantial opportunity for the growth of the global market.

RESTRAINING FACTORS

Surging Demand for Minimally Invasive Surgeries and Use of Hemostatic Devices to Hinder Growth

There is a gradual shift in patient preference from invasive surgeries to minimally invasive surgeries. Certain factors, such as decreased hospital stays, reduced cost, faster patient recovery, and superior patient comfort, are expected to increase the adoption of minimally invasive surgeries during the forecast period. The rising adoption of minimally invasive surgeries is eventually anticipated to reduce the need for blood conservation or allogeneic transfer as minimal blood is lost during these procedures.

For instance, according to an article published by the Journal of Cardiac Surgery in 2021, data was recorded in the medical records of 893 consecutive patients undergoing mitral valve reconstruction through a right mini-thoracotomy from 2010 to 2019. It was found that mitral valve surgery using a minimally invasive approach is a feasible treatment option for all-comers and is associated with excellent results. Additionally, adopting hemostatic devices to prevent heavy blood loss is expected to restrict the development of the global market.

Autotransfusion Devices Market Segmentation Analysis

By Product Type Analysis

Autotransfusion Systems Segment to Dominate due to Higher Adoption in Developed & Developing Countries

In terms of product type, the market is categorized into autotransfusion systems and consumables & accessories.

Autotransfusion systems are further classified as intraoperative autotransfusion systems, post-operative autotransfusion systems, and dual-mode autotransfusion systems. The increasing adoption of autotransfusion systems in developed and developing countries due to their efficiency in blood transfusion is expected to boost this segment's growth during the forecast period.

Also, improved flexibility, transfusion report generations, increasing technological advancements for better clinical outcomes and connectivity are projected to drive the growth of the dual-mode autotransfusion systems market by 2032.

Furthermore, the higher adoption and utilization of autotransfusion systems are anticipated to offer substantial opportunities for the growth of the consumables & accessories segment in the global market. This, combined with the growing emphasis on intraoperative cell salvage during major invasive surgeries, is expected to boost the growth of this segment during the forecast period.

By Application Analysis

Cardiovascular Surgeries Segment to Lead Backed by Growing Number of Surgical Procedures

On the basis of application, the market is segmented into cardiovascular surgeries, orthopedic surgeries, neurological surgeries, obstetrics & gynecological surgeries, and others.

In terms of revenue, the cardiovascular surgeries segment is estimated to dominate the global market, owing to the higher utilization of these devices during cardiovascular surgical procedures. Moreover, the increasing number of cardiovascular procedures, such as coronary artery bypass grafting (CABG), implantable cardioverter-defibrillator (ICD) & pacemaker implantations, heart transplantations, valve replacement surgeries, and others, will aid the growth of this segment.

The adoption of post-operative cell salvage in orthopedic surgeries is expected to drive the growth of the orthopedic surgeries segment. Additionally, the increasing number of invasive surgeries, such as caesarian section and others, is anticipated to drive the obstetrics & gynecological surgeries segment in the market with the highest CAGR in 2032.

By End-user Analysis

Increasing Number of Surgical Procedures Carried Out in Hospital Settings to Drive Growth of the Segment

On the basis of end-user, the market is segmented into hospitals and specialty clinics & others.

The hospitals segment is estimated to dominate the global market over the forecast period. The increasing number of cardiovascular and obstetrics & gynecological surgeries carried out in hospitals is projected to drive the segment growth during the forecast period.

In addition, certain factors such as evolving healthcare infrastructure in developing countries and increasing number of advanced healthcare facilities are expected to boost the adoption of devices for autotransfusion in user hospitals, which will eventually accelerate the growth of the hospital segment in the global market.

However, the surging adoption of intraoperative and post-operative cell salvage in specialty clinics, especially in developed regions, is anticipated to drive the specialty clinics & other segment moderately by 2032.

REGIONAL INSIGHTS

The market size in North America stood at USD 138.1 million in 2023. The increasing use of autologous blood transfusion in major cardiovascular & orthopedic surgeries, coupled with the presence of developed healthcare infrastructure, is anticipated to drive the market growth in the region during the forecast period. For instance, the American Association of Blood Bank guideline recommends that postoperative & intraoperative autotransfusion should be performed in surgeries where 20% of bleeding out of the total surgical bleeding is anticipated.

In Europe, the rapidly increasing number of surgeries in key countries such as the U.K., France, and Germany, coupled with a strong emphasis on adopting intraoperative and postoperative cell salvage techniques, is expected to offer substantial opportunity for the market to grow at a CAGR by 2032 in the region.

The market in Asia Pacific is expected to grow at the highest CAGR due to the entrance of new market players while growing awareness of cell salvage technologies is projected to drive the growth by 2032. Moreover, the rapidly rising number of surgical procedures and developing healthcare infrastructure in China and India are anticipated to offer significant growth opportunities in the region.

In the rest of the world, the increasing number of surgical procedures performed in countries, including Brazil, the UAE, and Saudi Arabia is anticipated to boost the demand for autotrantransfusion devices especially from small and mid-sized healthcare facilities.

List of Key Companies in Autotransfusion Devices Market

LivaNova Plc and Haemonetics Corporation to Dominate with Strong Product Offerings

The global market is highly consolidated as a limited number of players hold a majority of the autotransfusion devices market share. In 2021, LivaNova Plc., Haemonetics Corporation, and Fresenius SE & Co. KGaA dominated the market with their competitive product offerings. LivaNova Plc has a strong brand presence, robust distribution channels, and a strong product portfolio.

On the other hand, other established key players, such as Fresenius SE & Co. KGaA, are currently collaborating with other companies to establish their foothold in the global market.

• For instance, in November 2021, Fresenius SE & Co. KGaA announced a collaboration with Omnicell, Inc. with an aim to offer innovative new pharmacy technology to the U.S. hospitals and health systems.

The market shares of Haemonetics Corporation and Fresenius SE & Co. KGaA are anticipated to increase over the forecast period due to continuous product introductions, strategic distribution partnerships, and their focus on market penetration in developing regions. 

Other key players operating in the market are Medtronic, Beijing Jingjing Medical Equipment Co., Ltd., ProCell Surgical Inc., and BD (Becton, Dickinson and Company).

LIST OF KEY COMPANIES PROFILED:

• LivaNova PLC (U.K.)


• Medtronic (Ireland)


• Haematonics Corporation (U.S.)


• Fresenius SE & Co. KGaA (Germany)


• BD (Becton, Dickinson, and Company) (U.S.)


• Beijing Jingjing Medical Equipment Co., Ltd. (China)


• ProCell Surgical Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• February 2024: ProCell Surgical Inc. was successfully registered and certified to be compliant with the requirements of ISO 13485:2016 under the MDSAP scope. Additionally, ProCell received CE-marked approval for its Sponge Blood Recovery Unit, found to conform with Regulation (EU) 2017/745 for Medical Devices.


• March 2023: Haemonetics Corporation received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on next-generation software for the Cell Saver Elite+ Autotransfusion System.


• June 2020- ProCell Surgical Inc. announced the launch of ProCell, its first medical device designed to effectively automate the manual and outdated activity of surgical sponge-blood recovery for intraoperative autotransfusion.


• December 2019 - Haemonetics Corporation launched the Next Generation SafeTrace Tx Transfusion Management Software in North America. The newly released software provides an enhanced user experience and superior operational workflow, thereby enabling extended care quality.

REPORT COVERAGE

The global autotransfusion devices market report provides a detailed analysis of the market and focuses on key aspects such as company profiles, applications, product type, and end-user. Besides this, it offers insights into the overview of the market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation